10 of 32 FDA Vioxx Panelists Had Industry Ties / Cozy NIH Review "Clears" NIH Industry Ties

10 of 32 FDA Vioxx Panelists Had Industry Ties_NYT / Cozy NIH Review “Clears” NIH Industry Ties_WashPost Fri, 25 Feb 2005 The latest example of the corrupting influence of the pharmaceutical industry on health care policy is the composition of FDA’s advisory panel that last week endorsed the marketing of…

Fast growing business: Unethical clinical trials in India – Asia Times

Fast growing business: Unethical clinical trials in India – Asia Times Tue, 27 Jul 2004 Asia Times reports: “India increasingly emerges as a preferred destination for outsourcing clinical trials – testing of new drugs on humans – the country may also be heading toward providing the greatest source of human…

Doctors On the Take-Engaging in Vairous Dubious Activities for Cash / Stock Options

Doctors On the Take-Engaging in Vairous Dubious Activities for Cash / Stock Options Tue, 16 Aug 2005 A series of current articles in The Wall Street Journal, the Journal of the American Medical Association (JAMA), and the New York Times describe the many questionable non-medical income-producing activities that America¹s physicians…

Doctors Without Borders: Why you can’t trust medical journals anymore

Doctors Without Borders: Why you can’t trust medical journals anymore Tue, 13 Apr 2004 Related link: Hear an interview with Shannon Brownlee on NPR at: http://www.npr.org/features/feature.php?wfId=1874563 Doctors Without Borders in the Washington Monthly (excerpt below), looks at the intricate web of collaborating players in medicine who are financially tied one…

Marketing Drugs by Marketing Sex–Cheerleader Sales Reps

Marketing Drugs by Marketing Sex–Cheerleader Sales Reps Mon, 28 Nov 2005 Readers, but not the medical community, may be shocked by a front page story in The New York Times that sheds light on yet another unseemly pharmaceutical industry strategy for pushing brand name drugs. The industry’s most effective drug…

AMA Serves Pharma Marketing Priority/ FDA To Add Warnings on ADHD drugs–Concerta, Ritalin, Strattera, Adderall

AMA Serves Pharma Marketing Priority/ FDA To Add Warnings on ADHD drugs–Concerta, Ritalin, Strattera, Adderall Wed, 29 Jun 2005 The FDA is finally taking note of the fact that many drugs prescribed for the treatment of psychiatric problems are CAUSING serious psychiatric and cardiovascular problems in children and adolescents !…

Antipsychotic Drug Use Doubled since 1996 in Tennessee Children – Why?

Antipsychotic Drug Use Doubled since 1996 in Tennessee Children – Why? Thu, 2 Sep 2004 A Vanderbilt University study found that the use of antipsychotic drugs has doubled among poor children in Tennessee. “The increase, seen largely among children diagnosed with attention-deficit/hyperactivity disorder (ADHD), conduct disorder and affective disorders such…

NY Times Does it Again – Drug Advertisers Get Front Page Coverage to Boost SSRI Market

NY Times Does it Again – Drug Advertisers Get Front Page Coverage to Boost SSRI Market Wed, 2 Jun 2004 The New York Times saw fit to print a report about preliminary, unpublished findings of a study whose authors claim to have “found that Prozac helps teenagers overcome depression far…

Lies & Broken Promises – Drug firm Websites Fail to Disclose Test Data

Lies & Broken Promises_Drug firm Websites Fail to Disclose Test Data Sun, 9 Jan 2005 One year after PhRMA’s publicized proclamation of its “commitment to transparency” The Boston Globe reviewed pharmaceutical company websites searching for disclosure of clinical trial data. The Globe found that this voluntary approach failed miserably: “Last…

Conflicts of Interest policy – New York Times

Conflicts of Interest policy – New York Times Sun, 28 Mar 2004 To: ‘Executive-editor@nytimes’; ‘gcollins@nytimes’; ‘arosenthal@nytimes’; ‘pboffey@nytimes’; ‘lchang@nytimes’; ‘oped@nytimes’ Cc: ‘Daniel Okrent’ ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) Promoting openness and full disclosure https://ahrp.org FYI Friday’s New York Times included the following Editor’s Note on the paper’s Op Ed page:…